Samsung Biologics' share price surges with corona treatment contract

Established in April 2011 as an affiliate of Samsung Group, it runs a CMO business that consigns and produces advanced biopharmaceuticals from domestic and foreign pharmaceutical companies.

Starting cGMP production in 2018, it is operating 36.2 million liters of production facilities as of the end of 2019, and leaping to the world's No. 1 CMO based on production facilities by surpassing the leading companies in this market.

Samsung Bioepis and Akigen Biotech, subsidiaries of the company's biopharmaceutical research and development, are in the process of developing and commercializing biosimilars.

2020/08/02 - [KOSPI] - HDC Hyundai Industry Development entered into Asiana Airlines due diligence and acquisition review

2020/07/29 - [KOSPI] - POSCO Chemical, the next generation anode material development and EV beneficiary

2020/07/27 - [KOSPI] - Celltrion gains additional recognition in Europe with Ramshima SC